Brand-to-brand nonmedical switching among interleukin-17 inhibitors or other biologics: Implications of a formulary change
{{output}}
Background: In 2021, a large pharmacy benefit management organization (PBM) changed preferred agents on its national formulary from one branded interleukin (IL)-17 inhibitor (TxA) to another (TxB), prompting a nonmedical switch (... ...
